Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
$1.01
$-0.17
(-14.41%)
As on 26-Aug-2026 16:20EDT
Market cap
$35 Mln
Revenue (TTM)
$35 Mln
P/E Ratio
3.1
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$0.4
-
Face value
--
-
Shares outstanding
31,374,994
10 Years Aggregate
CFO
$-198.44 Mln
EBITDA
$-277.50 Mln
Net Profit
$-269.39 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
| -25.7 | -- | -14.4 | -43.6 | -44.8 | -30.3 | -32.4 |
|
BSE Sensex*
| -8.8 | 1.6 | 1.6 | -4.4 | 6.0 | 6.7 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
| 7.9 | -74.9 | -52.3 | 77.2 | -22.9 | 19.4 | -43.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
|
1.0 | 34.5 | 35.1 | 11.3 | 32.2 | 59.3 | 3.1 | 1.2 |
| 89.1 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 250.3 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 79.2 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.1 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 107.1 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 538.9 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 619.1 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 377.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 151.5 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting... radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York. Read more
-
Chairman & CEO
Mr. Sandesh C. Seth M.B.A., M.S.
-
Chairman & CEO
Mr. Sandesh C. Seth M.B.A., M.S.
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
What is the current share price of Actinium Pharmaceuticals Inc (Delaware) (ATNM) Today?
The share price of Actinium Pharmaceuticals Inc (Delaware) (ATNM) is $1.01 (NYSE) as of 26-Aug-2026 16:20 EDT. Actinium Pharmaceuticals Inc (Delaware) (ATNM) has given a return of -44.85% in the last 3 years.
What is the current PB & PE ratio of Actinium Pharmaceuticals Inc (Delaware) (ATNM)?
The P/E ratio of Actinium Pharmaceuticals Inc (Delaware) (ATNM) is 3.14 times as on 21-Aug-2026.
The P/B ratio of Actinium Pharmaceuticals Inc (Delaware) (ATNM) is 1.16 times as on 21-Aug-2026, a 78 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.25 |
5.42 |
2024 |
-1.03 |
1.20 |
2023 |
-2.88 |
3.86 |
2022 |
-8.28 |
4.11 |
2021 |
-5.23 |
1.76 |
What is the 52 Week High and Low of Actinium Pharmaceuticals Inc (Delaware) (ATNM)?
The 52-week high and low of Actinium Pharmaceuticals Inc (Delaware) (ATNM) are Rs 1.81 and Rs 0.95 as of 27-Aug-2026.
What is the market cap of Actinium Pharmaceuticals Inc (Delaware) (ATNM)?
Actinium Pharmaceuticals Inc (Delaware) (ATNM) has a market capitalisation of $ 35 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Actinium Pharmaceuticals Inc (Delaware) (ATNM)?
Before investing in Actinium Pharmaceuticals Inc (Delaware) (ATNM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.